Efficacy And Safety Of Liraglutide For Weight Loss In Bese Non-diabetic Adults

Background:Obesity is a chronic metabolic disease characterized by excessive accumulation of fat caused by the combination of genetic and environmental factors and many other factors.With the accelerating pace of life,increasing intake of high-calorie diet and insufficient exercise,the incidence of overweight/obesity is increasing year by year.Subsequently,the incidence of metabolic diseases such as hypertension,hyperglycemia and hyperlipidemia is also increasing,which has become one of the main causes of harm to human health.It is urgent to formulate a safe and effective weight loss program.Currently,it is considered that lifestyle intervention is a safe and effective treatment,while scientific diet and exercise intervention combined with reasonable drug therapy is a more effective and safer means of weight loss.In recent years,studies on weight loss in obese patients have gradually become a hot spot in clinical and scientific research.SCALE studies show that the application of Liraglutide in obese and pre-diabetic patients has achieved significant weight loss effect,but there are still insufficient studies on the application of this drug in obese non-diabetic patients in China.In this paper,the efficacy and safety of Liraglutide assisted lifestyle intervention and simple lifestyle intervention on weight loss in obese adults without diabetes were observed and compared.Objective:The purpose of this study was to compare the efficacy and safety of liraglutide and lifestyle intervention with lifestyle intervention alone in obese non-diabetic adults by observing the effects of liraglutide on body weight,body mass index,waist-to-hip ratio,blood sugar,blood lipids,liver and renal function and other indicators.This study provides a clinical reference and guidance for the use of GLP-1 receptor agonists in obese non-diabetic adults.Methods:A total of 65 obese non-diabetic adult patients admitted to the Department of Endocrinology,Huaihe Hospital of Henan University from November 2020 to May 2022 were selected,and 39 subjects were successfully screened according to the set inclusion and exclusion criteria,as follows: The patients were randomly divided into liraglutide group(n=19)and placebo group(n=20).The liraglutide group was given liraglutide injection 3.0mg/d subcutaneously,and the placebo group was given liraglutide mimetic,and both groups were given lifestyle intervention.The subjects’ gender,age,height,weight(Wt),body mass index(BMI),waist circumference(WC),waist-hip ratio(WHR),heart rate(HR),systolic blood pressure(SBP),diastolic blood pressure(DBP),fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c),2-hour postprandial blood glucose(2hPBG),The changes of blood lipid,liver function,kidney function and other general data were compared between the two groups after treatment,and the efficacy and safety of the two treatment regimens in obese non-diabetic people were observed.Results:1.Comparison of baseline indicators between liraglutide group and placebo group: there was no difference in sex,age,height,Wt,BMI,WC,WHR,SBP,DBP,FPG,2hPBG,HbA1 c,blood lipids,liver function,renal function,and pancreatic function(P > 0.05),indicating comparability.2.Primary efficacy: the changes of Wt,BMI,WC and WHR before and after treatment and the proportion of subjects with weight loss > 5% and 10% compared with baseline in the two groups(1)After 3 months of treatment,the Wt,BMI,WC and WHR in 2 groups were significantly lower than before treatment(P <0.05).Wt,BMI,WC and WHR were significantly lower in the liraglutide group than in the placebo group(P < 0.05).(2)After 3 months of treatment,more patients in the liraglutide group lost more than 5% and 10% of their baseline body weight compared with the placebo group.The total effective rate of liraglutide group(78.95%)was significantly higher than that of placebo group(20%),and which was statistically significant(P < 0.05).3.Secondary efficacy: the changes of SBP,DBP,FPG,HbA1 c,2hPBG,blood lipids,liver function,renal function and other indicators before and after treatment in the two groups(1)After 3 months of treatment,SBP and DBP in Liraglutide group were significantly lower than before treatment(P < 0.05).Compared with placebo group,systolic and diastolic blood pressure decreased significantly in Liraglutide group(P < 0.05).(2)After 3 months of treatment,there were no significant differences in FPG,HbA1 c,2hPBG,blood lipids,liver function,and renal function between the liraglutide group and the placebo group(P > 0.05).4.Safety analysisBy the end of the study,there was no severe hypoglycemia,acute pancreatitis,or allergic reaction in the two groups.There was no significant difference in the incidence of adverse reactions between the liraglutide group and the placebo group(26.3% vs 5.0%,P > 0.05).Conclusion:1.Liraglutide assisted lifestyle intervention is more effective in reducing Wt,BMI,WC and WHR than lifestyle intervention alone in overweight/obese non-diabetic adults.The proportion of patients who lost more than 5% and 10% of body weight was higher.2.Liraglutide assisted lifestyle intervention in the treatment of overweight/obese non-diabetic adults can significantly reduce the systolic and diastolic blood pressure of the subjects.3.Liraglutide assisted lifestyle intervention in the treatment of overweight/obese non-diabetic adults does not increase the incidence of serious adverse reactions,and has good drug safety.